Senzime Appoints Former Dräger Medical CEO Wolfgang Reim as New Senior Advisor to The Board

Rhea-AI Summary

Senzime (STO:SEZI)(OTCQX:SNZZF), a leading provider of perioperative precision-based patient monitoring solutions, has appointed Dr. Wolfgang Reim as the new senior advisor to its Board of Directors. Dr. Reim brings extensive experience from his previous roles, including CEO of Dräger Medical and the Ultrasound Division at Siemens Healthcare. His background includes serving on the boards of Elekta AB, GN Store Nord, Carl Zeiss, and Ondal Medical Systems. Senzime CEO Philip Siberg expressed high expectations for Dr. Reim's expertise in global commercialization and medical technologies, which are anticipated to support the company's rapid growth objectives.

Positive

• Appointment of experienced industry veteran Dr. Wolfgang Reim as senior advisor.
• Reim's previous roles include CEO at Dräger Medical and the Ultrasound Division at Siemens Healthcare.
• Background includes board positions at prominent companies like Elekta AB, GN Store Nord, Carl Zeiss, and Ondal Medical Systems.
• Expected to contribute significantly to Senzime's growth and market expansion.

Negative

• The announcement does not include any specific new product developments or immediate financial impacts.
• The focus on an advisory role may not directly influence short-term stock performance.
• Potential over-reliance on the advisor's experience without clear strategic initiatives outlined.

UPPSALA, SE / ACCESSWIRE / May 17, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime, an industry leader in perioperative precision-based patient monitoring solutions, today announced the appointment of Dr. Wolfgang Reim as new senior advisor to its Board of Directors.

Wolfgang Reim has a long medical industry career including positions as CEO of the Ultrasound Division of Siemens Healthcare, CEO of Dräger Medical during 2000-2006, and many Board and Chairman roles in companies including Elekta AB, GN Store Nord, Carl Zeiss and Ondal Medical Systems. Wolfgang Reim was born in 1956, resides in Germany and has a MSc and Doctors degree in Physics from the Federal Institute of Technology ETH in Zurich.

"We're honored to welcome Dr. Reim as senior advisor to Senzime. His global expertise, strong commercialization skills and experience in bringing world-class medical technologies to market will be highly beneficial to Senzime as we continue to execute our rapid growth journey", commented Senzime's CEO Philip Siberg.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com .

Attachments

Senzime appoints former Dräger Medical CEO Wolfgang Reim as new senior advisor to the board

SOURCE: Senzime

View the original press release on accesswire.com

FAQ

Who is the new senior advisor for Senzime as of May 2024?

Dr. Wolfgang Reim has been appointed as the new senior advisor to the Board of Directors of Senzime.

What is Dr. Wolfgang Reim's background?

Dr. Reim has held positions such as CEO of Dräger Medical and the Ultrasound Division of Siemens Healthcare, and he has served on boards of companies like Elekta AB and Carl Zeiss.

How might Dr. Wolfgang Reim's appointment impact Senzime's stock performance (SNZZF)?

While Dr. Reim's expertise is expected to support Senzime's growth, the announcement does not specify immediate financial impacts on the stock performance.

What are the potential benefits of Dr. Wolfgang Reim joining Senzime?

Dr. Reim's global commercialization skills and experience in bringing medical technologies to market are expected to be highly beneficial for Senzime's growth.